Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (ESOPEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02509286

Recruitment Status : Active, not recruiting

First Posted : July 28, 2015

Last Update Posted : November 4, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Clinical Trials Unit Freiburg

University of Freiburg

University of Leipzig

University of Luebeck

University of Hamburg-Eppendorf

Information provided by (Responsible Party):

Jens Hoeppner, University Hospital Schleswig-Holstein

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	April 2023
Estimated Study Completion Date :	June 2024

Publications:

Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Rothling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.

To Top